What is Spark Biomedical?
Founded in 2018, Spark Biomedical is at the forefront of medical technology, specializing in a drug-free, personalized wearable neurostimulation solution designed to combat opioid withdrawal. The company's approach is validated by a double-blind, randomized controlled clinical trial, targeting patients suffering from opioid use disorder. This significant backing positions Spark Biomedical to scale its operations and further its mission to provide effective, non-pharmacological treatment options.
How much funding has Spark Biomedical raised?
Spark Biomedical has raised a total of $31.2M across 2 funding rounds:
Other Financing Round
$16.2M
Series A
$15M
Other Financing Round (2023): $16.2M, investors not publicly disclosed
Series A (2025): $15M led by WAVE Ventures and Pathway To Cures
Key Investors in Spark Biomedical
WAVE Ventures
WAVE Ventures is an investor participating in the funding round, likely focused on innovative healthcare solutions.
Pathway To Cures
Pathway To Cures is an investor contributing to this funding round, suggesting a focus on advancing medical treatments.
What's next for Spark Biomedical?
With this major enterprise-level funding, Spark Biomedical is poised for significant expansion. The strategic investment will likely fuel further research and development, enhance manufacturing capabilities, and broaden market penetration. The company's focus on evidence-based, wearable technology for a critical public health issue suggests a trajectory of growth and impact within the healthcare sector. Future developments may include expanded clinical applications and strategic partnerships to accelerate adoption.
See full Spark Biomedical company page
